home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

308 rows where filing_period = "third_quarter", filing_year = 2024 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 308 ✖

filing_year 1

  • 2024 · 308 ✖

filing_period 1

  • third_quarter · 308 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3231916 HOLLAND & KNIGHT LLP abfde80a-14ab-40ce-87b1-1c455f9a501a Q3 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2024 third_quarter PHA Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-02T10:51:07-04:00
3232107 REPUBLIC CONSULTING, LLC 5fc1df71-9268-4dc6-8341-726e03734bf0 Q3 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2024 third_quarter PHA Monitor Health Data Policy. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-02T16:03:39-04:00
3232230 AMERICAN COLLEGE OF CLINICAL PHARMACY 41da2eef-7e12-4553-98b8-76dbc47f668c Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2024 third_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2024-10-03T11:00:22-04:00
3232358 MCDERMOTT+ LLC 7a568241-fed2-47a6-a77f-011f95e735eb Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2024 third_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-10-03T15:36:27-04:00
3232398 AEGIS LLC a82f58a9-86a4-4006-b2f7-3f0d42e8c4d1 Q3 AEGIS LLC 401108688 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2024 third_quarter PHA PBM reforms. 340B. IRA implementation. Drug pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2973 - Modernizing and Ensuring PBM Accountability Act. H.R.830 - HELP Copays Act. H.R.7085 - BIOSECURE Act. S.127 - Pharmacy Benefit Manager Transparency Act of 2023. S.1339 - Pharmacy Benefit Manager Reform Act H.R.3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-03T17:08:29-04:00
3232400 AEGIS LLC 0ee47b02-acb4-4961-b976-2316fb770b61 Q3 AEGIS LLC 401108688 TRIS PHARMA, INC. 2024 third_quarter PHA ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). HOUSE OF REPRESENTATIVES,Natl Highway Traffic Safety Administration (NHTSA),SENATE 50000   0 0 2024-10-03T17:09:00-04:00
3232406 2359 STRATEGIES dd0f4f46-dcce-4e2e-87e7-fb9ecb0a5bca Q3 2359 STRATEGIES 401106114 TRAVERE THERAPEUTICS 2024 third_quarter PHA Orphan Drug Act HOUSE OF REPRESENTATIVES,SENATE 12000   0 0 2024-10-03T18:25:31-04:00
3232460 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION aa501068-6234-4921-9d9f-8075fee452ad Q3 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2024 third_quarter PHA Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2024-10-04T08:07:29-04:00
3232731 RED+BLUE STRATEGIES 3f10a316-e565-4ea3-aa28-a064a7e54a8a Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2024 third_quarter PHA H. R. 9747 - Continuing Appropriations and Extensions Act, 2025 - Issues related to funding government departments and agencies responsible for administering programs that support prescription drug coverage. CMS Rules and Regulations focused on the promulgation of the Medicare Part D program. S. 1542 - The DRUG Act - Issues related to ensuring that policies contemplated by Congress allow entities providing coverage of prescription medications have the tools they need to keep drugs affordable and accessible in the commercial market. H.R. 7623 - Telehealth Modernization Act of 2024 - Support for the underlying telemedicine extension, yet concern for the commercial delinking offset included in the legislation. S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees. S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients. H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act -… Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-10-05T12:31:06-04:00
3232899 MASON STREET CONSULTING, LLC c123c323-9dd3-40a6-b0f7-62efe24f1e91 Q3 MASON STREET CONSULTING, LLC 401105150 CAPITAL RX INC. 2024 third_quarter PHA PBM Reform. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-10-07T06:14:00-04:00
3233064 DAVE KOLBE CONSULTING bf2a57bc-a7df-4ddc-881f-661964abada3 Q3 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2024 third_quarter PHA H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-07T12:09:49-04:00
3233221 RAY ANDERSON 9e65d762-93ce-43dc-ac10-4e30a977303f Q3 RAY ANDERSON 401105487 340B HEALTH 2024 third_quarter PHA Contract Pharmacy-HR 7635, The 340B PATIENTS Act of 2024 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program) Letter to HHS Secretary Becerra Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES     0 0 2024-10-07T17:36:02-04:00
3233222 RAY ANDERSON 2f6bd4af-77c1-404f-893f-69ad77de8053 3A RAY ANDERSON 401105487 340B HEALTH 2024 third_quarter PHA Contract Pharmacy-HR 7635, The 340B PATIENTS Act of 2024 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program) Letter to HHS Secretary Becerra Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES   15000 0 0 2024-10-07T18:14:14-04:00
3233228 STUMPTOWN STRATEGIES 2e974ce4-4284-4b67-b9f7-c20e02837748 Q3 STUMPTOWN STRATEGIES 401106433 PRIME THERAPEUTICS 2024 third_quarter PHA Introduction to Prime to Members of the 118th Congress Monitoring PBM Legislation HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-10-07T18:31:05-04:00
3233576 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 47d565fb-92e3-43d0-b1e5-fcde65ea19f1 Q3 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2024 third_quarter PHA CCAGW Hosts Briefing on 340B Drug Discount Program CCAGW Hosts Briefing on 340B Drug Discount Program CCAGW Shares Blog Post on 340B Drug Discount Program CCAGW Shares Blog Post on 340B Drug Discount Program HOUSE OF REPRESENTATIVES,SENATE   420000 0 0 2024-10-08T13:23:37-04:00
3233591 POLSINELLI PC 1ea0688d-ff91-4ca2-bb61-687694468c2a Q3 POLSINELLI PC 314911 RESQ PHARMA 2024 third_quarter PHA FDA Regulatory Issues HOUSE OF REPRESENTATIVES 10000   0 0 2024-10-08T14:01:14-04:00
3233713 ACG ADVOCACY d3b37f5c-f3a4-4385-a7ba-f7511d0ac52d Q3 ACG ADVOCACY 2057 WALGREEN CO. 2024 third_quarter PHA Drug pricing policy issues. Data privacy. Provider status legislation. Counterfeiting issues. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-10-08T15:11:13-04:00
3233733 OMEGA STRATEGIES LLC (DC) 5810ed86-ee6c-4267-bf85-3f05ecb21d38 Q3 OMEGA STRATEGIES LLC (DC) 401108551 ON DEMAND PHARMACEUTICALS 2024 third_quarter PHA Advocated on issues related to appropriations and defense industrial base policy. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-10-08T15:28:16-04:00
3233899 WEST FRONT STRATEGIES LLC 9017dcaa-8a03-47bb-b194-9dad215a1d6e Q3 WEST FRONT STRATEGIES LLC 401103493 WALGREEN CO. 2024 third_quarter PHA Issues related to pharmacy, military pharmacies, pharmacist provider status, and Medicare reimbursement, including Equitable Community Access to Pharmacist Services Act (H.R. 1770 and S. 2477). HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-10-08T22:32:34-04:00
3234073 FAMILIES USA FOUNDATION, INC. 237e24fd-86f1-4931-90d0-069a0625ad1e Q3 FAMILIES USA FOUNDATION, INC. 14108 FAMILIES USA FOUNDATION INC 2024 third_quarter PHA s.150Affordable Prescriptions for Patients Act of 2023To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2024-10-09T11:10:22-04:00
3234280 LMH STRATEGIC SOLUTIONS 168d625f-d2f9-4dc8-a36a-6fc2e4432254 Q3 LMH STRATEGIC SOLUTIONS 401108183 AVADEL PHARMACEUTICALS, PLC 2024 third_quarter PHA Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-10-09T14:52:45-04:00
3234284 LMH STRATEGIC SOLUTIONS b3b24423-a540-4314-acea-fa693e033887 Q3 LMH STRATEGIC SOLUTIONS 401108183 GLAXOSMITHKLINE LLC 2024 third_quarter PHA General healthcare issues impacting GSK. H.R.7085 - BIOSECURE Act. H.R.830 - HELP Copays Act. H.R.5378 - Lower Costs, More Transparency Act. S.1542 - DRUG Act. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-10-09T14:55:58-04:00
3234296 LMH STRATEGIC SOLUTIONS 32568a51-1d72-461e-b2d3-5bf7c974e63b Q3 LMH STRATEGIC SOLUTIONS 401108183 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2024 third_quarter PHA Prescription drug payment reform. Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-10-09T15:01:37-04:00
3234400 CASSIDY & ASSOCIATES, INC. c536a96f-1f81-489e-bc18-597332cb851f Q3 CASSIDY & ASSOCIATES, INC. 8453 HIMS & HERS HEALTH, INC. (FORMERLY HIMS, INC) 2024 third_quarter PHA Compounding / telehealth HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-10-09T16:18:43-04:00
3234642 BUCHANAN INGERSOLL & ROONEY PC 7b293afd-980f-484b-80dc-7d24c594b9e9 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2024 third_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-10-10T10:53:21-04:00
3234695 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2ecc71b6-e867-41db-bea2-87f04d4c49a9 Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2024 third_quarter PHA OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee Drug Enforcement Administration Pseudoephedrine quotas Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 118712   0 0 2024-10-10T11:25:08-04:00
3234723 MR. H.R. BERT PENA 5d0d038b-24b9-4332-a09c-2ef173324e0a Q3 MR. H.R. BERT PENA 400323519 MARGO RX LLC(DBA RICHARD'S PHARMACY) 2024 third_quarter PHA PBM AND DRUG PRICES Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES     0 0 2024-10-10T12:11:31-04:00
3234879 THORSEN FRENCH ADVOCACY LLC c353f91b-f215-4d16-bab3-918b19ee2e28 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2024 third_quarter PHA Drug Shortages. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-10-10T14:10:28-04:00
3234908 THORSEN FRENCH ADVOCACY LLC b96251e3-9e9e-49a5-b942-869df3c9e956 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2024 third_quarter PHA Issues related to drug pricing. Issues realted to anti-competitive tactics in the pharmaceutical marketplace. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-10T14:18:17-04:00
3235880 TRUSYNERGY 96d3d243-be3d-4ccb-bfea-b624fcd99200 Q3 TRUSYNERGY 401107715 BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) 2024 third_quarter PHA Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-10-12T11:56:34-04:00
3235996 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 6211d5ab-e322-4f2a-bece-cafafdedff54 Q3 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2024 third_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-12T19:01:42-04:00
3236983 PRIME POLICY GROUP cbb39a2e-f809-4de9-8821-ce3a8958f6cc Q3 PRIME POLICY GROUP 400532589 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2024 third_quarter PHA H.R.1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; S.2666 - EPCS 2.0 Act HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2024-10-14T14:32:25-04:00
3236989 WINNING STRATEGIES WASHINGTON 644687ac-0f20-49e8-b4ba-0e5e5cc701ac Q3 WINNING STRATEGIES WASHINGTON 50796 KALEO 2024 third_quarter PHA Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-10-14T14:36:26-04:00
3237026 RESOLUTE-DC e7da9a39-e368-4e17-8d77-ba84853b14b2 Q3 RESOLUTE-DC 401106654 MODEL MEDICINES 2024 third_quarter PHA Introduce Model Medicines and how the company is innovating at the intersection of data science, biology and drug development. Health & Human Services, Dept of (HHS)     0 0 2024-10-14T14:53:18-04:00
3237043 PRIME POLICY GROUP 5e399cc4-8a2a-4f4d-bbd3-a910db5ffb8f 3T PRIME POLICY GROUP 400532589 QUVA PHARMA, INC. 2024 third_quarter PHA Legislation and regulation impacting outsourcing facilities regulated under Section 503B under the Federal Food, Drug, and Cosmetic Act Centers For Medicare and Medicaid Services (CMS),SENATE 50000   0 1 2024-10-14T15:03:29-04:00
3237046 INDEPENDENT PHARMACY COOPERATIVE 4b4c25ef-6366-4f5e-93df-35fa4f4389a4 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2024 third_quarter PHA IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act IPC supports S. 127 Pharmacy Benefit Manager Transparency Act IPC supports (H.R. 1770/S. 2477) The Equitable Community Access to Pharmacists Services Act IPC supports FDA delay of DSCSA enhanced data compliance-request for comments CMS Implementation of PY 2024 Medicare Part D drug rule-comments CMS Implementation of drug provisions of the IRA 2022-comments Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2024-10-14T15:05:11-04:00
3237353 KOUNTOUPES DENHAM CARR & REID, LLC d0d43f3e-69ee-4bee-a1a8-7c8af6301796 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ABBOTT LABORATORIES 2024 third_quarter PHA Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R.1770/S.2477, the Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-14T18:47:46-04:00
3237527 COREWELL HEALTH eb0bc388-daeb-462b-9d23-3ade4037536d Q3 COREWELL HEALTH 298455 COREWELL HEALTH 2024 third_quarter PHA 340B PBM Reform/Oversight Transparency and high costs associated with prescription drugs HOUSE OF REPRESENTATIVES,SENATE   140000 0 0 2024-10-15T08:32:44-04:00
3237784 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) e86e2c46-950b-485d-b41e-eccb79174d92 Q3 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 28264 NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) 2024 third_quarter PHA Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2024-10-15T10:45:24-04:00
3238019 NATIONAL RIGHT TO LIFE COMMITTEE b1823a99-db7f-4d8b-a94e-accf6a547d25 Q3 NATIONAL RIGHT TO LIFE COMMITTEE 28481 NATIONAL RIGHT LIFE COMMITTEE 2024 third_quarter PHA Contacts in support of proposed rule, "Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation," 88 FR 12875 (March 1, 2023), (RIN): 1117-AB40, Docket ID DEA-407 due to impact of assisted suicide drugs. Contacts regarding vending machine dispensing of chemical abortion drugs. Drug Enforcement Administration (DEA),SENATE   38000 0 0 2024-10-15T11:58:39-04:00
3238046 NATIONAL RIGHT TO LIFE COMMITTEE 29501d1c-59fa-4cdf-ad98-2c1c133a71c4 Q3 NATIONAL RIGHT TO LIFE COMMITTEE 28481 NATIONAL RIGHT LIFE COMMITTEE 2024 third_quarter PHA Contacts in support of proposed rule, "Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation," 88 FR 12875 (March 1, 2023), (RIN): 1117-AB40, Docket ID DEA-407 due to impact of assisted suicide drugs. Contacts regarding vending machine dispensing of chemical abortion drugs. Drug Enforcement Administration (DEA),SENATE   38000 0 0 2024-10-15T12:05:53-04:00
3238248 MANATOS & MANATOS 0650c181-03cb-4ec0-b6c3-e4019013d8bd Q3 MANATOS & MANATOS 23634 VANDA PHARMACEUTICALS INC 2024 third_quarter PHA FDA approval of specific medical drugs HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-10-15T13:22:20-04:00
3238422 BROWNSTEIN HYATT FARBER SCHRECK, LLP 49a05523-f710-4e40-bfb3-b9d419486ad5 Q3 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2024 third_quarter PHA H.R. 1770 Equitable community access to pharmacist services act Issues related to drug pricing reform and transparency Issues related to access and distribution of pharmaceutical products Issues related to Artificial Intelligence in healthcare HOUSE OF REPRESENTATIVES 50000   0 0 2024-10-15T14:22:20-04:00
3238453 PANNONE LOPES DEVEREAUX & O'GARA LLC 1253ee57-5b3a-4bea-8b8e-378d22f74358 Q3 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2024 third_quarter PHA Prescription drug pricing.   9000   0 0 2024-10-15T14:26:17-04:00
3238673 PUBLIC CITIZEN deed46c0-9af6-475c-b873-34577378d9cc Q3 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2024 third_quarter PHA government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   65265 0 0 2024-10-15T15:11:52-04:00
3238697 WEST FRONT STRATEGIES LLC 9e19ad8c-dfed-4776-9085-2cd78e4297b4 Q3 WEST FRONT STRATEGIES LLC 401103493 VIATRIS INC 2024 third_quarter PHA Issues related to e-labeling. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-15T15:24:42-04:00
3238812 1607 STRATEGIES, LLC 9e969425-3fac-4b13-8ec8-e018a408ed00 Q3 1607 STRATEGIES, LLC 401105461 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2024 third_quarter PHA S. 2793, Modernizing and Ensuring PBM Accountability Act, all provisions. H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act, all provisions. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-15T16:15:41-04:00
3239017 KOUNTOUPES DENHAM CARR & REID, LLC 8731a176-e643-4eb4-9b18-69cf603b9d2b Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 AMERICAN KRATOM ASSOCIATION 2024 third_quarter PHA Issues related to Food and Drug Administration regulatory and consumer access. Issues related to H.R. 5905, Federal Kratom Consumer Protection Act, and the Fiscal Year 2025 Agriculture Appropriations bills. HOUSE OF REPRESENTATIVES 50000   0 0 2024-10-15T17:01:57-04:00
3239103 KOUNTOUPES DENHAM CARR & REID, LLC 6236de19-7dda-4276-a7d9-bf1ee1cbaf55 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2024 third_quarter PHA Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R.1770/S. 2477, The Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-15T17:22:53-04:00
3239420 WAKEFERN FOOD CORP. 3c80b395-c6cd-490c-9206-c6db8c84b3bd Q3 WAKEFERN FOOD CORP. 400588798 WAKEFERN FOOD CORP. 2024 third_quarter PHA Comprehensive pharmacy benefit manager (PBM)/DIR fee reform H.R. 5378 - "Lower Costs, More Transparency Act" S. 3430 - "Better Mental Health Care, Lower-Cost Drugs, and Extenders Act" S. 2973 - "Modernizing and Ensuring PBM Accountability Act" Legislative measures add more transparency HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-10-16T09:23:21-04:00
3239492 UNIVERSITY OF IOWA 37a1cfa6-d120-4b43-a69e-5b99aab72075 Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2024 third_quarter PHA N/A HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2024-10-16T09:47:58-04:00
3239582 KOUNTOUPES DENHAM CARR & REID, LLC c67e6031-2714-40fa-a0ac-5ce4a88d7cc0 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2024 third_quarter PHA General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-16T10:14:21-04:00
3239687 KOUNTOUPES DENHAM CARR & REID, LLC 156d758b-e789-4266-8548-301af67f54e4 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2024 third_quarter PHA Issues related to drug pricing transparency. Issues related to pharmacy benefit managers. Issues related to testing, vaccination and treatment including H.R.1770 and S.2477, the Equitable Community Access to Pharmacist Services Act. Issues related to pharmaceutical access and affordability. Issues related to pharmaceutical supply chains. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-10-16T10:43:33-04:00
3240093 VENN STRATEGIES c26f9816-cde1-475c-ac2e-1dc6f2f72255 Q3 VENN STRATEGIES 65191 THE PERSONAL CARE PRODUCTS COUNCIL 2024 third_quarter PHA Issues related to personal care products, including but not limited to sunscreen and the humane cosmetic acts. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-10-16T12:17:41-04:00
3240328 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) ff50a6fa-b248-48f0-a328-e12bcdbd361f Q3 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2024 third_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   497548 0 0 2024-10-16T13:31:27-04:00
3241510 SHIONOGI INC. 8a9b35ef-a6f8-4227-b453-a8e688ffad63 Q3 SHIONOGI INC. 401107081 SHIONOGI INC. 2024 third_quarter PHA Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355); Rare Pediatric Disease Priority Review Voucher reauthorization. (H.R. 3433, HR 7384, S. 4583) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2024-10-16T17:13:22-04:00
3241563 PRINTING UNITED ALLIANCE 7c7e2bb8-867a-41e9-a5e0-36d95d716e31 Q3 PRINTING UNITED ALLIANCE 401105682 PRINTING UNITED ALLIANCE 2024 third_quarter PHA Retention of FDA regulations mandating use of pharmaceutical information and prescriber data on paper. Support of H.R. 1173 (118th Congress): Patients Right to Know Their Medication Act. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2024-10-16T17:32:24-04:00
3241669 BLUE SHIELD OF CALIFORNIA e2d77a42-dbd5-406e-8eb6-fbbfa9ecde43 Q3 BLUE SHIELD OF CALIFORNIA 6518 BLUE SHIELD OF CALIFORNIA 2024 third_quarter PHA Affordable Care Act Tax Credits Pharmacy Benefit Manager Reforms HOUSE OF REPRESENTATIVES,SENATE   120000 0 0 2024-10-16T19:18:44-04:00
3242154 ELI LILLY AND COMPANY 7d3b1d21-97aa-4db0-bccc-842b46db6ba4 Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2024 third_quarter PHA Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act HOUSE OF REPRESENTATIVES,SENATE   1795000 0 0 2024-10-17T10:18:05-04:00
3242258 HEALTHSPERIEN 9bb791ee-4065-4998-8d7b-7d26e42db0d5 Q3 HEALTHSPERIEN 401103150 EXACT CARE PHARMACY 2024 third_quarter PHA Advocate for codifying definition for long-term care pharmacy in the home setting. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 35000   0 0 2024-10-17T10:35:22-04:00
3242476 THE CONSILIO GROUP 9e630b18-47d2-4797-94e8-9c4e584e7634 Q3 THE CONSILIO GROUP 400374717 PARATEK PHARMACEUTICALS 2024 third_quarter PHA Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office 36000   0 0 2024-10-17T10:58:19-04:00
3242571 WHITMER & WORRALL, LLC 456d88c8-3457-4f86-910c-ff855beeffa8 Q3 WHITMER & WORRALL, LLC 292892 CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) 2024 third_quarter PHA Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-17T11:04:34-04:00
3242943 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH 569604c7-864e-479c-b592-f3e430675e1f Q3 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH 401107274 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH 2024 third_quarter PHA Any bills or provisions related to the 340b drug discount program. HOUSE OF REPRESENTATIVES,SENATE   110000 0 0 2024-10-17T11:43:35-04:00
3243025 CAPITOL COUNSEL LLC 2d0d78e7-c653-4f44-bc03-b76d431b328b Q3 CAPITOL COUNSEL LLC 313715 EMD SERONO, INC. 2024 third_quarter PHA Issues regarding the availability and pricing of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-10-17T11:56:09-04:00
3243072 ARNOLD & PORTER KAYE SCHOLER LLP 76755f1d-9041-46e8-84ef-72eca2eff8e8 Q3 ARNOLD & PORTER KAYE SCHOLER LLP 4301 NOVO NORDISK, INC. 2024 third_quarter PHA Issues related to pharmacy benefit managers (PBMs) and the 340B Program. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2024-10-17T12:04:10-04:00
3243197 POWERS PYLES SUTTER & VERVILLE, P.C. 49cd3f60-28c1-48bc-9674-3fcbc3b8a1c4 Q3 POWERS PYLES SUTTER & VERVILLE, P.C. 32008 NATIONAL ASSOCIATION OF SPECIALTY PHARMACY 2024 third_quarter PHA Pharmacy market competition. Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2024-10-17T12:23:53-04:00
3243230 DESIMONE CONSULTING, LLC f026d099-3ca2-478b-aacc-dec97b131f22 Q3 DESIMONE CONSULTING, LLC 400931695 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2024 third_quarter PHA Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform; H.R.8574, To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to the Ensuring Pathways to Innovative Cures (EPIC) Act, H.R.7174. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-17T12:30:03-04:00
3243271 BLUECROSS BLUESHIELD OF TENNESSEE c8b572a7-46be-4d79-a1ad-2cbf2c27a5f3 Q3 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2024 third_quarter PHA Prescription Drug Pricing Reform; Pharmacy Benefit Managers; Delinking PBM language; Prior Authorization S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage HOUSE OF REPRESENTATIVES,SENATE   160000 0 0 2024-10-17T12:41:19-04:00
3243370 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 7508310f-3b3b-41f4-a4cf-48b28a6cebe2 Q3 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2024 third_quarter PHA Gene Therapies; Prescription Drug Affordability HR 6094, PROTECT Rare Act, by Rep. Doris Matsui (D-CA). To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition. HR 9070, Affordable Prescriptions for Patients Act of 2024, by Rep. Darrell Issa (R-CA). To amend title 35, United States Code, to prohibit product hopping. S 150, Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping. S 775, Increasing Transparency in Generic Drug Applications Act, by Sen. Margaret Hassan (D-NH). To provide for increased transparency in generic drug applications. S 1542, DRUG Act, by Sen. Roger Marshall (R-KS). To improve services provided by pharmacy benefit managers. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   220000 0 0 2024-10-17T13:04:20-04:00
3243383 HIGHMARK, INC. cc15e2f6-db22-467b-a5f9-37fec2f8ffe1 Q3 HIGHMARK, INC. 18238 HIGHMARK INC 2024 third_quarter PHA Issues: Insulin Copay Caps, Drug Pricing, Pharmacy Benefit Manager (PBM) Reform, Generic Drug Manufacturing, GLP-1s Bills: Senate Finance Committee PBM Reform Framework H.R. 5378 - The Lower Costs, More Transparency Act - A bill to require health care providers and insurers to disclose certain information about health care costs. It also establishes requirements for certain payment methodologies under Medicare and Medicaid and extends several public health programs. H.R. 1488/S. 954 - The Affordable Insulin Now Act -- A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 127. - The Pharmacy Benefit Manager Transparency Act - This bill generally prohibits pharmacy benefit managers (PBMs) from engaging in certain practices when managing the prescription drug benefits under a health insurance plan, including charging the plan a different amount than the PBM reimburses the pharmacy. S.1339 - The Pharmacy Benefit Manager Reform Act - A bill to provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. H.R.2679 - The Pharmacy Benefits Manager Accountability Act - A bill to amend the Public Health Service Act, the Employee Retirement Income Security Act, and the Internal Revenue Code of 1984 to increase oversight of pharmacy benefits manager services, and for other purposes. H.R. 3561 - PATIENT Act of 2023 - This bill expands hospital price transparency requirements and establishes additional reporting requirements with respect to prescription drugs and pharmacy benefit managers (PBMs). H.R. 2630/S. 652 - The Safe Step Act -- This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription … HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2024-10-17T13:04:52-04:00
3243400 AMERICAN VETERINARY MEDICAL ASSOCIATION 42201d7e-20d1-488e-a1f9-d46a73243f79 Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2024 third_quarter PHA H.R. 1839/S. 993 Combatting Illicit Xylazine Act H.R. 4531 SUPPORT Act HOUSE OF REPRESENTATIVES,SENATE   330000 0 0 2024-10-17T13:08:47-04:00
3243418 GUIDEWELL MUTUAL HOLDING CORPORATION 14ff0b2a-4c81-4995-a51c-54ea22731eaf Q3 GUIDEWELL MUTUAL HOLDING CORPORATION 401103191 GUIDEWELL MUTUAL HOLDING CORPORATION 2024 third_quarter PHA Gene Therapies; Prescription Drug Affordability HR 6094, PROTECT Rare Act, by Rep. Doris Matsui (D-CA). To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition. HR 9070, Affordable Prescriptions for Patients Act of 2024, by Rep. Darrell Issa (R-CA). To amend title 35, United States Code, to prohibit product hopping. S 150, Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping. S 775, Increasing Transparency in Generic Drug Applications Act, by Sen. Margaret Hassan (D-NH). To provide for increased transparency in generic drug applications. S 1542, DRUG Act, by Sen. Roger Marshall (R-KS). To improve services provided by pharmacy benefit managers. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   20000 0 0 2024-10-17T13:11:33-04:00
3243430 ISEMAN & ASSOCIATES LLC da94157a-cad7-487a-821c-035306e8c064 Q3 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2024 third_quarter PHA Monitoring biotech legislation; prescription drug prices; Infrastructure Legislation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-10-17T13:13:43-04:00
3243690 NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION 429f7406-46a2-4fdf-85bb-c423ab3cfb30 Q3 NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION 27786 NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION 2024 third_quarter PHA 340B drug pricing program Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-10-17T13:54:49-04:00
3243875 ASSOCIATION FOR ACCESSIBLE MEDICINES 0f0b3377-e797-48a8-b699-69fa5a758241 Q3 ASSOCIATION FOR ACCESSIBLE MEDICINES 16032 ASSOCIATION FOR ACCESSIBLE MEDICINES 2024 third_quarter PHA Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024. S.1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023. H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act. Drug Shortages. S.2362 - Drug Shortage Prevention Act. S.2305: Biosimilar Red Tape Elimination Act. FDA Inspections. Drug-Device Combination Products. Third Party Drug Quality Studies. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act. Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),HOUSE OF REPRESENTATIVES,SENATE   530000 0 0 2024-10-17T14:11:49-04:00
3243910 THE MADISON GROUP 26ed94f3-8db5-485d-9998-1020068ba080 Q3 THE MADISON GROUP 284050 WALGREEN CO. 2024 third_quarter PHA Issues pertaining to the retail pharmacy industry, access to and delivery of COVID-19 vaccinations and pharmacy benefit managers (PBMs). H.R. 1770/S. 2477, the Equitable Community Access to Pharmacist Services Act; Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2024-10-17T14:14:25-04:00
3243967 FORBES-TATE 2f967441-211b-400d-91af-14e4a0fd4cd8 Q3 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2024 third_quarter PHA Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency and reform; Issues related to S.127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S.1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R.3561 - PATIENT Act of 2023; Issues related to S.2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R.5378 - the Lower Costs, More Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-17T14:20:50-04:00
3243985 60 PLUS ASSOCIATION 81f1e378-a4e7-4d5b-8168-9a90fa9e71ef Q3 60 PLUS ASSOCIATION 41988 60 PLUS ASSOCIATION 2024 third_quarter PHA Urging Members of Congress and the Biden Administration to support and advance the Equitable Community Access to Pharmacist Services Act (H.R. 1770, S. 2477) to provide payment for essential pharmacist services under Medicare Part B and ensure pharmacists can continue to protect seniors from the threat of COVID-19, influenza, RSV, strep throat, pneumococcal, and hepatitis B. HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 0 2024-10-17T14:21:58-04:00
3244100 ARENTFOX SCHIFF LLP 3f4b3b32-e3a8-4095-83d7-da3fe43cd798 Q3 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2024 third_quarter PHA Prescription drug pricing generally Pharmacy Benefit Manager (PBM) reform generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions S. 1339 (Pharmacy Benefit Manager Reform Act), regarding Pharmacy Benefit Manager (PBM) reform S. 3430 (Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023), regarding Pharmacy Benefit Manager (PBM) reform H.R. 5378 (Lower Costs, More Transparency Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 6283 (DRUG Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 9096 (Pharmacists Fight Back Act), regarding Pharmacy Benefit Manager (PBM) reform, all provisions HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-17T14:28:01-04:00
3244550 TWENTY-FIRST CENTURY GROUP, INC. 386e0f7b-50dc-4582-b548-ed30d28c10c5 Q3 TWENTY-FIRST CENTURY GROUP, INC. 38687 CARDINAL HEALTH, INC. 2024 third_quarter PHA Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; drug shortages; Food as Medicine; Drug Supply Chain Security Act (DSCSA), and the healthcare supply chain. HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2024-10-17T15:04:26-04:00
3244558 MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) fc35851c-8022-4bb8-ada3-7142017298a7 Q3 MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) 24566 MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS 2024 third_quarter PHA H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   640000 0 0 2024-10-17T15:05:08-04:00
3244820 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 0f613df5-6423-4a9b-a3df-bbf088a4b82c Q3 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 28526 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 2024 third_quarter PHA H.R. 6283,"DRUG Act"- legislation that impacts Pharmacy Benefit Managers (PBMs), it could have the unintended consequences of reducing mail volume and increasing the costs/premiums of employer sponsored health programs. The NRLCA has not taken a position on this legislation. S. 1542, "DRUG Act"- Senate companion bill to H.R. 6283, the NRLCA has not taken a position on this bill. HOUSE OF REPRESENTATIVES,SENATE   125000 0 0 2024-10-17T15:30:17-04:00
3244907 WAXMAN STRATEGIES 69318c02-5db3-4c1a-b1c8-8a9ce740139d Q3 WAXMAN STRATEGIES 401103693 340B HEALTH 2024 third_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2024-10-17T15:38:53-04:00
3245154 DENTONS US LLP 8a2cbcab-a5fd-40be-a215-f061a91afa38 Q3 DENTONS US LLP 36105 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA 2024 third_quarter PHA Federal issues impacting workforce and innovation in the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-10-17T16:10:42-04:00
3245995 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION dc8ec398-c6b7-4e3e-8a5d-7343fc002a91 Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2024 third_quarter PHA H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act" (Docket No. FDA-2023-N-4806); Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024; H.R.2882, the Further Consolidated Appropriations Act, 2024; Comments on implementation and enforcement of recent changes to USP Chapter <797>, regarding the Compounded Sterile Preparations (CSPs) in Category 3 to the FDA; Comments to FDA on "Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment Under the Drug Supply Chain Security Act" [Docket No.FDA-2024-N-0668]; Comments to FDA on " Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act"[Docket No. FDA-2023-N-0061]; H.R.9096, the Pharmacists Fight Back Act; Comments to FDA on Docket No. FDA-2023-N-4806 - Implementing Interoperable Systems and Processes for Enhanced Drug Distribution S… Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   380000 0 0 2024-10-17T18:41:36-04:00
3246133 BURRELL INTERNATIONAL GROUP LLC 15bd7508-0788-4348-9554-c3b31743364d Q3 BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2024 third_quarter PHA LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY25 Defense Appropriation for broad-spectrum antivirals, FY25 LHHS for long covid and cocaine overdose funding HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-10-17T20:00:53-04:00
3246134 BURRELL INTERNATIONAL GROUP LLC 86148853-2ea6-4bca-a1f8-e9559b4bc965 Q3 BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2024 third_quarter PHA FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-17T20:01:42-04:00
3246209 DA VINCI GROUP 561a562b-6355-4636-9109-e56031b24a7e Q3 DA VINCI GROUP 11548 BOESEN & SNOW, LLC 2024 third_quarter PHA Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-10-17T20:33:55-04:00
3246262 FORBES-TATE 60907bd4-389b-48be-8f19-57970b9cf499 Q3 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2024 third_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-10-17T20:45:34-04:00
3246304 FORBES-TATE efda9ea2-2f51-4a0a-97bd-c33e29a1dc7e Q3 FORBES-TATE 400976792 PHRMA 2024 third_quarter PHA Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2024-10-17T20:55:14-04:00
3246326 BROWNSTEIN HYATT FARBER SCHRECK, LLP 272616ac-9f58-433b-b92d-2a0ea4977e42 Q3 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 LILLY USA, LLC 2024 third_quarter PHA Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2024-10-17T20:58:44-04:00
3246369 E3 STRATEGIC CONSULTING GROUP 7f2662d7-c51e-4166-88c6-b9fd9d7bfb18 Q3 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2024 third_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act; HR 6283 - The Drug Act; HR 5378 - Lower Costs, More Transparency Act HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-10-17T21:16:46-04:00
3246410 POLARIS GOVERNMENT RELATIONS, LLC adb27fbe-1d48-44a0-ba21-0e8a9634b75c Q3 POLARIS GOVERNMENT RELATIONS, LLC 307730 CIGNA CORPORATION 2024 third_quarter PHA Drug pricing and issues facing the pharmacy benefit manager industry generally HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2024-10-17T21:28:44-04:00
3246716 BALLARD PARTNERS 70a0fa19-cf6f-4acf-9905-943e500253ea Q3 BALLARD PARTNERS 401104288 THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) 2024 third_quarter PHA 340B Drug Discount Program. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-10-18T06:35:33-04:00
3246798 VAN SCOYOC ASSOCIATES fb6cdc7e-fb8f-48fc-9d2c-0e118414b871 Q3 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2024 third_quarter PHA Temperature monitoring technology issues, as follows: H.R.8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2025 HOUSE OF REPRESENTATIVES 30000   0 0 2024-10-18T07:34:42-04:00
3246912 340B HEALTH 0e60e76f-6249-40b1-bb9a-a30e6ddef7d9 Q3 340B HEALTH 316434 340B HEALTH 2024 third_quarter PHA The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635 and S. 5021, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act: H.R.8144 - Rural 340B Access Act of 2024 Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE   345454 0 0 2024-10-18T08:28:24-04:00
3246971 AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION bf1cc0f8-b89b-429a-ad20-2907161e9592 Q3 AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION 1331 AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION 2024 third_quarter PHA Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   1060000 0 0 2024-10-18T08:54:03-04:00
3247519 TARPLIN, DOWNS & YOUNG, LLC 2298002a-6270-4767-8567-eead5cea783e Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2024 third_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2024-10-18T10:13:04-04:00
3247558 CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. f16638e0-a156-40da-b43c-6d51af33cb53 Q3 CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. 401103415 CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. 2024 third_quarter PHA strengthening the 340B program for childrens hospitals. HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2024-10-18T10:16:24-04:00
3247901 AKIN GUMP STRAUSS HAUER & FELD 375f6df0-9912-44e8-9a51-bb693c1aa52e Q3 AKIN GUMP STRAUSS HAUER & FELD 682 CENTRIENT PHARMACEUTICALS LLC 2024 third_quarter PHA Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE 30000   0 0 2024-10-18T10:40:23-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2158.177ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API